PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
52 hedge funds and large institutions have $245M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 15 increasing their positions, 1 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
Holders
52
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$87.2M | |
| 2 | +$11.2M | |
| 3 | +$11.2M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.93M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.42M |
Top Sellers
| 1 | -$1.16M | |
| 2 | -$407K | |
| 3 | -$217K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$14.4K |